Molecular Health GmbH announced that it has received €25 million in funding led by existing investor, dievini Hopp BioTech holding GmbH & Co. KG on November 16, 2015. The company plans to use the proceeds to further build their commercial infrastructure and drive product adoption.
“Big data is largely driving decision-making for today’s physicians, diagnostic labs, and pharmaceutical companies. However, the sheer volume of data that exists today and its continuous, rapid expansion makes it increasingly complicated to digest and apply in a practical way,” said Lutz Voelker, Chief Executive Officer of Molecular Health.
Molecular Health GmbH develops a computational system that transforms molecular data into clinically actionable information to provide various cancer treatment options for cancer patients. The company was founded in 2004 and is financed by dievini Hopp BioTech, an investment vehicle of former SAP CEO and founder Dietmar Hopp. Molecular Health is based in Heidelberg, Germany, but also has offices in Boston, MA and Houston, TX in the US. As of 2014, Molecular Health has about 100 employees in the United States and Europe. In 2015 the company plans to grow substantially. The company has raised €100 million in funding till date.
Molecular Health press release (English)